Sign Out
The concomitant use of MAO inhibiting compounds is contraindicated. Hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. The potentiation of adverse effects can be serious, or even fatal. When it is desired to substitute imipramine in patients receiving a MAO inhibitor, as long as interval should elapse as the clinical situation will allow, with a minimum of 14 days. Initial dosage should be low and increases should be gradual and cautiously prescribed.
Patients with a known hypersensitivity to this compound should not be given the drug.
